3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
76
Precursor Cell Lymphoblastic Leukemia-Lymphoma
19
Burkitt Lymphoma
17
Recurrence
10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
9
Neoplasms, Plasma Cell
5
Lymphoma
5
Leukemia, Biphenotypic, Acute
5
Immunoglobulin Light-chain Amyloidosis
5
Smoldering Multiple Myeloma
4
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasms
4
Leukemia
4
Neoplasm Metastasis
3
Down Syndrome
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Waldenstrom Macroglobulinemia
2
Prostatic Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma, B-Cell
2
Lung Neoplasms
2
Leukemia, Hairy Cell
2
Hodgkin Disease
2
Fatigue
2
Brain Neoplasms
2
Blastic Plasmacytoid Dendritic Cell Neoplasm
2
Interventions
pembrolizumab
119
Cisplatin
33
lenvatinib
29
Carboplatin
28
Paclitaxel
27
Docetaxel
14
Pemetrexed
13
Fluorouracil
12
Capecitabine
11
Saline Solution
10
Oxaliplatin
10
Gemcitabine
10
Albumin-Bound Paclitaxel
7
olaparib
6
Leucovorin
6
Bevacizumab
6
epacadostat
5
belzutifan
5
Etoposide
5
Cetuximab
5
130-nm albumin-bound paclitaxel
5
trifluridine tipiracil drug combination
3
regorafenib
3
patritumab deruxtecan
3
enzalutamide
3
enfortumab vedotin
3
durvalumab
3
Surgical Procedures, Operative
3
Radiotherapy
3
Levoleucovorin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Calcium Dobesilate
×
1 year
×
Clear all
NCT03834506
2025-07-18
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3
Completed
1,030 enrolled
24 charts